Sexual desire

Mar 05, 2020

Addyi Demonstrates Significant Improvements in Female Sexual Function for Arousal, Desire, Lubrication, Satisfaction, and Orgasm

Oct 16, 2019

Vyleesi(TM) Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

Sep 09, 2019

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market to 2027: Affordable Reimbursement Scenario for Pharmacotherapy Employed in the Treatment of HSDD

Sep 04, 2019

FDA Removes Alcohol Ban with Addyi - the First-and-Only Non-Hormonal Treatment for Hypoactive (Low) Sexual Desire Disorder (HSDD)

Jun 21, 2019

FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women

Apr 12, 2019

The Food and Drug Administration (FDA) Determines that Women Taking Addyi May Safely Consume Alcohol

Jan 04, 2019

S1 Biopharma Announces Expanded Analysis of Phase 2a Data on Lorexys(TM) for Treatment of Hypoactive Sexual Desire Disorder Based on PGIC Scale to be Presented at 2019 ISSWSH/ISSM Joint Meeting

Jun 04, 2018

Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

Mar 26, 2018

Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women

Mar 12, 2018

Mayo Clinic Proceedings Publishes First Consensus Clinical Management of HSDD in Women Authored by ISSWSH